Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety of Varenicline Tartrate ( CP-526,555) for Smoking Cessation

NCT00143299 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00143299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00143299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety of Varenicline Tartrate ( CP-526,555) for Smoking Cessation
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2003
Completion date
March 31, 2005
Enrollment
375
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation